Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

By G. Linette, E. Stadtmauer, M. Maus, A. Rapoport, B. Levine, Lyndsey Emery, L. Litzky, A. Bagg, B. Carreno, P. Cimino and 13 more. Blood, 2013

1,129 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

TRUCKs: the fourth generation of CARs (2015, background): “The severity of clinical symptoms correlated with tumor burden and CAR T-cell dose [14,22,23].”
Toxicities of chimeric antigen receptor T cells: recognition and management. (2016, neutral): “This toxicity has not been documented in clinical trials ofCARs, but it has been observed in clinical trials of T cells genetically modified to express T-cell receptors.(33,52,53)”
The Principles of Engineering Immune Cells to Treat Cancer (2017, background): “In a second trial testing an independently derived MAGE-A3 TCR isolated from a patient that was affinity enhanced by phage display, patients died from cardiac toxicity (Linette et al., 2013).”
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response (2014, background): “In addition, the adoptive transfer of autologous PBMC transduced with anHLA-A1 restricted,MAGE-A3–reactive TCR containing four a chain amino acid substitutions that were introduced to enhance antigen recognition resulted in cardiac arrest and the deaths of the first two patients treated on this prot”
Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry (2016, neutral): “01; SB ENST00000307712 H3F3C RIKQTARK T4I HLA-A* 03:01 Chr12:31792156 Mel15 5% 48:6 63:0 (3-10) 1614; 3.”